Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to the development and licensing of its small-molecule antiviral therapeutic, ravidasvir (PPI-668) in the treatment of hepatitis C virus (HCV) infection. With a compound targeting the NS5A protein of HCV, Presidio is positioned to compete in the HCV therapy market (see Programs & Pipeline for more details). Presidio’s goal is to advance ravidasvir (PPI-668), a potent pan-genotypic antiviral with convenient once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance, into additional clinical trials.